Company
Meridian Bioscience
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
18
510(k), De Novo and PMA
Device trials
17
As lead sponsor, any status
Adverse event reports
4
Received Nov 1, 2025 to Nov 20, 2026
Recall records
22
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Meridian Bioscience, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 18 since 2015.
- Revogene510(k)
K243922 · Decided Mar 20, 2025 · 90 days after receipt
Device type: Real Time Nucleic Acid Amplification System (OOI) · Laboratory Medicine & Pathology
K230901 · Decided Jul 3, 2023 · 94 days after receipt
Device type: Helicobacter Pylori (LYR) · Laboratory Medicine & Pathology
- Curian® Shiga Toxin510(k)
K222829 · Decided Apr 17, 2023 · 210 days after receipt
Device type: Antigens, All Types, Escherichia Coli (GMZ) · Laboratory Medicine & Pathology
15 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- BreathID 13C-Methacetin Breath Test for Detecting CirrhosisPivotal-lookingCompleted
NCT00736840 · 414 participants · Start Aug 2008 · Primary completion Sep 2009
Device: c13 methacetin solution with breath analyzer · For: Chronic Liver Disease
Sites: Los Angeles, California; Detroit, Michigan; Cleveland, Ohio · 11 sites in all
NCT01851252 · 19 participants · Start Oct 2013 · Primary completion Aug 2017
Device: Methacetin (with Breath testing device) · For: Chronic Liver Disease; Cirrhosis; Esophageal Varices and 2 more
Sites: Haifa, Israel
NCT02143778 · 246 participants · Start Nov 2014 · Primary completion Dec 2018
Device: Methacetin Breath Test · For: Patients With Compensated Liver Cirrhosis
Sites: New Haven, Connecticut; Durham, North Carolina; Richmond, Virginia · 8 sites in all
14 more trials with a free account
Reports received
4
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
3
75% of reports
Injury reports
1
25% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 1 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 3 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 3 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 1 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300Open, Classified
Z-1019-2026 · Started Dec 5, 2025 · Posted by FDA Jan 5, 2026
Reason given: The affected lots show a decline in performance over time, which may lead to false-negative results.
Cause as FDA categorized it: Under Investigation by firm · Device type: C. Difficile Toxin Gene Amplification Assay (OZN)
- Meridian Bioscience, alethia c. Difficile, Catalog Number 480050, Nucleic Acid Amplification Test AssayOpen, Classified
Z-0568-2026 · Started Oct 7, 2025 · Posted by FDA Nov 19, 2025
Reason given: The cap on the reaction buffer tube may be missing the black rubber gasket resulting in the potential for leakage and reduced buffer volume.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: C. Difficile Nucleic Acid Amplification Test Assay (OMN)
- Meridian Bioscience, Group B Streptococcus, Catalog Number 480050, Nucleic Acid Amplification Test AssayOpen, Classified
Z-0569-2026 · Started Oct 7, 2025 · Posted by FDA Nov 19, 2025
Reason given: The cap on the reaction buffer tube may be missing the black rubber gasket resulting in the potential for leakage and reduced buffer volume.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test (NJR)
19 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.